NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

著者: Mark A. Socinski, Ben Creelan, Leora Horn, Martin Reck, Luis Paz‐Ares, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, William J. Geese, Prabhu Bhagavatheeswaran, A. Chen, David P. Carbone - Annals of Oncology 2016 被引用: 111